These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 33776946)
1. Editorial: The Role of Ceramides in Diabetes and Cardiovascular Disease. Summers SA Front Endocrinol (Lausanne); 2021; 12():667885. PubMed ID: 33776946 [No Abstract] [Full Text] [Related]
2. Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure. Park TS; Goldberg IJ Heart Fail Clin; 2012 Oct; 8(4):633-41. PubMed ID: 22999245 [TBL] [Abstract][Full Text] [Related]
3. Heart in diabetes: a microvascular disease. Laakso M Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S145-9. PubMed ID: 21525446 [No Abstract] [Full Text] [Related]
4. The role of cardiac lipotoxicity in the pathogenesis of diabetic cardiomyopathy. Ussher JR Expert Rev Cardiovasc Ther; 2014 Mar; 12(3):345-58. PubMed ID: 24552544 [TBL] [Abstract][Full Text] [Related]
5. [Iatrogenic hypoglycemia and cardiovascular risk in type 2 diabetes]. Consoli A; Di Fulvio P G Ital Cardiol (Rome); 2012 Dec; 13(12):787-92. PubMed ID: 23196681 [No Abstract] [Full Text] [Related]
6. The Role of Ceramides in Diabetes and Cardiovascular Disease Regulation of Ceramides by Adipokines. Field BC; Gordillo R; Scherer PE Front Endocrinol (Lausanne); 2020; 11():569250. PubMed ID: 33133017 [TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of diabetic cardiomyopathy. Bugger H; Abel ED Diabetologia; 2014 Apr; 57(4):660-71. PubMed ID: 24477973 [TBL] [Abstract][Full Text] [Related]
8. Myocardial fatty acid metabolism and lipotoxicity in the setting of insulin resistance. Kok BP; Brindley DN Heart Fail Clin; 2012 Oct; 8(4):643-61. PubMed ID: 22999246 [TBL] [Abstract][Full Text] [Related]
9. Altered mitochondrial metabolism in the insulin-resistant heart. Makrecka-Kuka M; Liepinsh E; Murray AJ; Lemieux H; Dambrova M; Tepp K; Puurand M; Käämbre T; Han WH; de Goede P; O'Brien KA; Turan B; Tuncay E; Olgar Y; Rolo AP; Palmeira CM; Boardman NT; Wüst RCI; Larsen TS Acta Physiol (Oxf); 2020 Mar; 228(3):e13430. PubMed ID: 31840389 [TBL] [Abstract][Full Text] [Related]
10. [New drugs for type 2 diabetes: expanding cardiovascular protection beyond type 2 diabetes?]. Mannucci E G Ital Cardiol (Rome); 2012 Dec; 13(12 Suppl 1):3S. PubMed ID: 23258122 [No Abstract] [Full Text] [Related]
16. Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling. Smani T; Gallardo-Castillo I; Ávila-Médina J; Jimenez-Navarro MF; Ordoñez A; Hmadcha A Curr Med Chem; 2019; 26(22):4166-4177. PubMed ID: 28545369 [TBL] [Abstract][Full Text] [Related]
17. Sphingolipid Metabolism: New Insight into Ceramide-Induced Lipotoxicity in Muscle Cells. Bandet CL; Tan-Chen S; Bourron O; Le Stunff H; Hajduch E Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678043 [TBL] [Abstract][Full Text] [Related]
18. Role of ceramides in the pathogenesis of diabetes mellitus and its complications. Mandal N; Grambergs R; Mondal K; Basu SK; Tahia F; Dagogo-Jack S J Diabetes Complications; 2021 Feb; 35(2):107734. PubMed ID: 33268241 [TBL] [Abstract][Full Text] [Related]
19. Mitochondrial complex I deficiency and cardiovascular diseases: current evidence and future directions. Forte M; Palmerio S; Bianchi F; Volpe M; Rubattu S J Mol Med (Berl); 2019 May; 97(5):579-591. PubMed ID: 30863992 [TBL] [Abstract][Full Text] [Related]
20. Critical role of the epicardium in mediating cardiac inflammation and fibrosis in patients with type 2 diabetes. Packer M Diabetes Obes Metab; 2019 Aug; 21(8):1765-1768. PubMed ID: 31144444 [No Abstract] [Full Text] [Related] [Next] [New Search]